Read by QxMD icon Read

HPV testing

shared collection
21 papers 0 to 25 followers podcast on HPV screening. Check our work on MedPageToday and rate us on iTunes.
By Joe Weatherly FM/Hospitalist-CoFounder of QuestioningMedicine and PCRAP contributor.
Sara E Forhan, Catherine C Godfrey, D Heather Watts, Carol L Langley
BACKGROUND: Cervical cancer, almost all of which is caused by human papillomavirus, accounts for 12% of female cancers worldwide and is more common among HIV-infected women. Nine of 10 deaths from cervical cancer occur in low- and middle-income countries (LMICs). Simple screening methods and outpatient treatment of precursor lesions save lives but the benefit of these interventions among HIV-infected women is uncertain. OBJECTIVE: We reviewed evidence of the effects of screening with visual inspection with acetic acid (VIA), and outpatient treatment for cervical precancer among HIV-infected women in LMIC...
April 15, 2015: Journal of Acquired Immune Deficiency Syndromes: JAIDS
Thomas C Wright, Mark H Stoler, Catherine M Behrens, Abha Sharma, Guili Zhang, Teresa L Wright
OBJECTIVES: ATHENA evaluated the cobas HPV Test as the primary screen for cervical cancer in women ≥25years. This reports the 3-year end-of-study results comparing the performance of HPV primary screening to different screening and triage combinations. METHODS: 42,209 women ≥25years were enrolled and had cytology and hrHPV testing. Women with abnormal cytology (≥atypical squamous cells of undetermined significance) and those HPV positive were referred to colposcopy...
February 2015: Gynecologic Oncology
Nancy E Joste, Brigitte M Ronnett, William C Hunt, Amanda Pearse, Erika Langsfeld, Thomas Leete, MaryAnn Jaramillo, Mark H Stoler, Philip E Castle, Cosette M Wheeler
BACKGROUND: The New Mexico HPV Pap Registry was established to measure the impact of cervical cancer prevention strategies in the United States. Before widespread human papillomavirus (HPV) vaccine implementation, we established the baseline prevalence for a broad spectrum of HPV genotypes across the continuum of cervical intraepithelial neoplasia (CIN) and cancer. METHODS: A population-based sample of 6,272 tissue specimens was tested for 37 HPV genotypes. The number of specimens tested within each diagnostic category was: 541 negative, 1,411 CIN grade 1 (CIN1), 2,226 CIN grade 2 (CIN2), and 2,094 CIN grade 3 (CIN3) or greater...
January 2015: Cancer Epidemiology, Biomarkers & Prevention
Emilie Garnaes, Katalin Kiss, Luise Andersen, Marianne H Therkildsen, Maria B Franzmann, Bettina Filtenborg-Barnkob, Estrid Hoegdall, Lene Krenk, Michael Josiassen, Christel B Lajer, Lena Specht, Kirsten Frederiksen, Lennart Friis-Hansen, Finn C Nielsen, Susanne K Kjaer, Bodil Norrild, Christian von Buchwald
The aim was to explore whether the incidence of tonsillar squamous cell carcinomas (TSCCs) increased in Eastern Denmark, 2000-2010, and whether human papillomavirus (HPV) could explain the increase, and to assess the association of HPV prevalence with gender, age, and origin (i.e., the certainty of tonsillar tumor origin). We applied HPV DNA PCR and p16 immunohistochemistry to all TSCCs registered in the Danish Head and Neck Cancer Group (DAHANCA) and in the Danish Pathology Data Bank (n = 632). Pathologists reviewed and subdivided the tumors into two groups: specified and nonspecified TSCCs...
May 1, 2015: International Journal of Cancer. Journal International du Cancer
Alyce A Chen, Daniëlle A M Heideman, Debby Boon, Tarik Gheit, Peter J F Snijders, Massimo Tommasino, Silvia Franceschi, Gary M Clifford
UNLABELLED: Human papillomavirus 45 (HPV45) is a member of the HPV18-related alpha-7 species and accounts for approximately 5% of all cervical cancer cases worldwide. This study evaluated the genetic diversity of HPV45 and the association of HPV45 variants with the risk of cervical cancer by sequencing the entire E6 and E7 open reading frames of 300 HPV45-positive cervical samples from 36 countries. A total of 43 HPV45 sequence variants were identified that formed 5 phylogenetic sublineages, A1, A2, A3, B1, and B2, the distribution of which varied by geographical region...
April 2014: Journal of Virology
Philip E Castle, William C Hunt, Erika Langsfeld, Cosette M Wheeler
OBJECTIVE: To investigate the risk of cervical precancer and cancer associated with detection of human papillomavirus (HPV) 6, 11, and 42. METHODS: We used data from the New Mexico Human Papillomavirus Pap Registry. A stratified sample of 59,644 residual cervical cytology specimens from a population of 379,000 underwent HPV genotyping. We measured the 3-year cumulative incidence of cervical intraepithelial neoplasia grade 2 or more severe (CIN 2+) and grade 3 or more severe (CIN 3+) after detection of single HPV 6, 11, or 42 infections or single or multiple infections of HPV 6, 11, or 42 ("HPV 6, 11, 42, or combinations"; n=581)...
January 2014: Obstetrics and Gynecology
Nicolas Wentzensen, Martha Nason, Mark Schiffman, Lori Dodd, William C Hunt, Cosette M Wheeler
BACKGROUND: Multiple human papillomavirus (HPV) genotypes may be independently or synergistically associated with risk of high-grade squamous intraepithelial lesions (HSILs). We evaluated the risk of HSIL in women concomitantly infected with multiple HPV genotypes. METHODS: A population-based stratified sample of 59 664 cervical cytology specimens from women residing in New Mexico were evaluated for cytologic abnormalities and HPV genotypes. We calculated the risk of HSIL in women infected with a single HPV genotype and the risk in those infected with multiple HPV genotypes...
March 2014: Journal of Infectious Diseases
Thomas C Wright, Mark H Stoler, Catherine M Behrens, Abha Sharma, Keerti Sharma, Raymond Apple
Although it is recognized that cervical cytology is highly subjective, and that there is considerable interlaboratory variation in how slides are evaluated, little is known as to how this impacts the performance of cytology. In the ATHENA trial, liquid-based cytology specimens from 46,887 eligible women ≥21 years of age were evaluated at four large regional US laboratories, providing a unique opportunity to evaluate the impact of interlaboratory variations on the performance of cervical cytology. All women with abnormal cytology (atypical squamous cells of undetermined significance or higher) were referred to colposcopy, as were all high-risk human papillomavirus (hrHPV)-positive women ≥25 years of age and a random subset of those ≥25 years of age who were negative by both hrHPV testing and cytology...
April 15, 2014: International Journal of Cancer. Journal International du Cancer
Arundhati Rao, Maria Teresa Sandri, Mario Sideri, Stephen Young, Abha Sharma, Catherine Behrens
BACKGROUND: The increasing importance of high-risk human papillomavirus (hrHPV) testing in cervical cancer screening warrants evaluation of HPV DNA tests with an equivocal zone requiring retesting of samples in the low positive range. OBJECTIVES: To compare the results of the digene hc2 High Risk HPV DNA Test (hc2), which has a manufacturer's recommended retesting zone with the cobas HPV Test, a real-time polymerase chain reaction amplification test without an equivocal range...
September 2013: Journal of Clinical Virology: the Official Publication of the Pan American Society for Clinical Virology
Sarah Preisler, Matejka Rebolj, Anette Untermann, Ditte Møller Ejegod, Elsebeth Lynge, Carsten Rygaard, Jesper Bonde
New commercially available Human Papillomavirus (HPV) assays need to be evaluated in a variety of cervical screening settings. Cobas HPV Test (cobas) is a real-time PCR-based assay allowing for separate detection of HPV genotypes 16 and 18 and a bulk of 12 other high-risk genotypes. The aim of the present study, Horizon, was to assess the prevalence of high-risk HPV infections in an area with a high background risk of cervical cancer, where women aged 23-65 years are targeted for cervical screening. We collected 6,258 consecutive cervical samples from the largest cervical screening laboratory in Denmark serving the whole of Copenhagen...
2013: PloS One
Susan Hariri, Elizabeth R Unger, Suzanne E Powell, Heidi M Bauer, Nancy M Bennett, Karen C Bloch, Linda M Niccolai, Sean Schafer, Martin Steinau, Lauri E Markowitz
BACKGROUND: Two vaccines protect against human papillomaviruses (HPV) 16 and 18, which cause 70% of cervical cancer and 50% of cervical intraepithelial neoplasia 2/3 and adenocarcinoma in situ (CIN2+). Monitoring HPV types in CIN2+ may be used to assess HPV vaccine impact. METHODS: As part of a multisite vaccine impact monitoring project (HPV-IMPACT), biopsy specimens used to diagnose CIN2+ were obtained for HPV DNA typing for women aged 18-39 years. RESULTS: Among 4,121 CIN2+ cases reported during 2008-2009 in 18- to 39-year-old women 3058 (74...
December 15, 2012: Journal of Infectious Diseases
Robert Marshall Austin
No abstract text is available yet for this article.
June 2012: American Journal of Clinical Pathology
Mark H Stoler, Thomas C Wright, Abha Sharma, Guili Zhang, Raymond Apple, Teresa L Wright, Catherine M Behrens
We have previously shown that human papillomavirus (HPV) genotyping, using the cobas HPV Test (Roche Molecular Systems, Pleasanton, CA), can be used to identify women with atypical squamous cells of undetermined significance (ASC-US) at the highest risk for cervical intraepithelial neoplasia (CIN) grade 2 or worse. We investigated the impact of age stratification on the risk of CIN 2 or worse in women with ASC-US and the performance of HPV genotyping in different age strata. The sensitivity of the cobas HPV Test was 93...
February 2012: American Journal of Clinical Pathology
Thomas C Wright, Mark H Stoler, Catherine M Behrens, Raymond Apple, Toniann Derion, Teresa L Wright
OBJECTIVE: The objective of the study was to describe baseline data from Addressing the Need for Advanced HPV Diagnostics, a prospective, multicenter US cervical cancer screening trial. STUDY DESIGN: A total of 47,208 women aged 21 years or older undergoing routine screening were enrolled; liquid-based cytology and human papillomavirus (HPV) testing were performed. Women with abnormal cytology underwent colposcopy, as did high-risk HPV (hrHPV)-positive women and a random subset of women negative by both tests aged 25 years or older...
January 2012: American Journal of Obstetrics and Gynecology
Philip E Castle, Mark H Stoler, Thomas C Wright, Abha Sharma, Teresa L Wright, Catherine M Behrens
BACKGROUND: The ATHENA study was designed to assess the performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping compared with liquid-based cytology for cervical cancer screening in a large US population aged 21 years and older. We did a subanalysis of this population to compare the screening performance of the cobas HPV test versus liquid-based cytology in women aged 25 years and older, and assess management strategies for HPV-positive women. METHODS: Women aged 25 years or older who were attending routine cervical screening were enrolled from 61 clinical centres in 23 US states...
September 2011: Lancet Oncology
A Szarewski, W A J Poppe, S R Skinner, C M Wheeler, J Paavonen, P Naud, J Salmeron, S-N Chow, D Apter, H Kitchener, X Castellsagué, J C Teixeira, J Hedrick, U Jaisamrarn, G Limson, S Garland, B Romanowski, F Y Aoki, T F Schwarz, F X Bosch, D M Harper, K Hardt, T Zahaf, D Descamps, F Struyf, M Lehtinen, G Dubin
In the Phase III PATRICIA study (NCT00122681), the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine (Cervarix(®), GlaxoSmithKline Biologicals) was highly efficacious against HPV-16/18 infections and precancerous lesions in women HPV-16/18 deoxyribose nucleic acid (DNA) negative and seronegative at baseline. We present further data on vaccine efficacy (VE) against HPV-16/18 in the total vaccinated cohort including women who may have been exposed to HPV-16/18 infection before vaccination. In women with no evidence of current or previous HPV-16/18 infection (DNA negative and seronegative), VE was 90...
July 1, 2012: International Journal of Cancer. Journal International du Cancer
Mark Schiffman, Andrew G Glass, Nicolas Wentzensen, Brenda B Rush, Philip E Castle, David R Scott, Julie Buckland, Mark E Sherman, Greg Rydzak, Peter Kirk, Attila T Lorincz, Sholom Wacholder, Robert D Burk
BACKGROUND: Human papillomavirus (HPV) DNA testing is more sensitive than cytology for detection of cervical intraepithelial neoplasia grade 3 and cancer (≥CIN3). Adding HPV testing to cytology is recommended for women ≥30 but long-term prospective studies of HPV testing are rare. METHODS: Beginning in 1989-1990, ~20,000 women in a prepaid health maintenance organization (median age = 34) were followed passively by recommended annual cytology. We tested archived cervicovaginal lavage specimens collected at enrollment, primarily by MY09-MY11 PCR-based methods, for carcinogenic HPV types...
July 2011: Cancer Epidemiology, Biomarkers & Prevention
Mark H Stoler, Thomas C Wright, Abha Sharma, Raymond Apple, Karen Gutekunst, Teresa L Wright
This study evaluated the clinical performance of the cobas 4800 HPV Test (Roche Molecular Systems, Pleasanton, CA) for high-risk human papillomavirus (HR-HPV) testing with individual HPV-16/HPV-18 genotyping in women 21 years or older with atypical squamous cells of undetermined significance (ASC-US). Women (N = 47,208) were recruited in the United States during routine screening, and liquid-based cytology and HPV testing were performed. The ASC-US prevalence was 4.1% (1,923/47,208), and 1,578 women underwent colposcopy with valid results...
March 2011: American Journal of Clinical Pathology
Mark H Einstein, Mira Baron, Myron J Levin, Archana Chatterjee, Robert P Edwards, Fred Zepp, Isabelle Carletti, Francis J Dessy, Andrew F Trofa, Anne Schuind, Gary Dubin
This observer-blind study compared the prophylactic human papillomavirus (HPV) vaccines, Cervarix (GlaxoSmithKline) and Gardasil (Merck), by assessing immunogenicity and safety through one month after completion of the three-dose vaccination course. Women (n = 1106) were stratified by age (18-26, 27-35, 36-45 years) and randomized (1:1) to receive Cervarix (Months 0, 1, 6) or Gardasil (Months 0, 2, 6). At Month 7 after first vaccination, all women in the according-to-protocol cohort who were seronegative/DNA negative before vaccination for the HPV type analyzed had seroconverted for HPV-16 and HPV-18 serum neutralizing antibodies, as measured by pseudovirion-based neutralization assay (PBNA), except for two women aged 27-35 years in the Gardasil group who did not seroconvert for HPV-18 (98%)...
October 2009: Human Vaccines
J Paavonen, P Naud, J Salmerón, C M Wheeler, S-N Chow, D Apter, H Kitchener, X Castellsague, J C Teixeira, S R Skinner, J Hedrick, U Jaisamrarn, G Limson, S Garland, A Szarewski, B Romanowski, F Y Aoki, T F Schwarz, W A J Poppe, F X Bosch, D Jenkins, K Hardt, T Zahaf, D Descamps, F Struyf, M Lehtinen, G Dubin
BACKGROUND: The human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine was immunogenic, generally well tolerated, and effective against HPV-16 or HPV-18 infections, and associated precancerous lesions in an event-triggered interim analysis of the phase III randomised, double-blind, controlled PApilloma TRIal against Cancer In young Adults (PATRICIA). We now assess the vaccine efficacy in the final event-driven analysis. METHODS: Women (15-25 years) were vaccinated at months 0, 1, and 6...
July 25, 2009: Lancet
2015-03-18 01:12:13
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"